Washington University spinout Nexgenia is to work with Seattle Children’s Research Institute (SCRI) on advancing new immunotherapy treatments for cancer.
SCRI, one of the three institutes behind immunotherapy blockbuster spinout Juno Therapeutics, will be working with Nexgenia on developing nanoparticles which can improve the efficiency of immunotherapies.
Spun out from Washington in 2011, Nexgenia is working on cell separation technologies. Under the collaboration, the two will be using the technology to target and separate cells to use in immunotherapy.
SCRI is funding the partnership, although it did not disclose how much it will be providing.
